Subscribe
Subscribe
Picture of V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.
Icon-linkedin Link
Picture of V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.
Icon-linkedin Link

Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19

The opioid epidemic: solutions to a painful problem

How changing diets gave rise to the world’s deadliest diseases

Cell therapies: opportunities and challenges

Potential impact of the corona crisis on the life sciences industry

Augustine Therapeutics: bridging the valley of death with VIB Discovery Sciences

Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding [...]

Why Are Start-Ups Such Hotbeds For Innovation?

V-Bio Ventures invests in RootWave in a EUR 6.5 M Series A financing to develop and market electrical weed killing solutions

Ghent (Belgium), 20th of January 2020 - Today V-Bio Ventures announces its investment in RootWave, a pioneer in electrical weed killing solutions. RootWave secured ca. EUR 6.5m in a Series A investment round led by V-Bio Ventures (Belgium) and Rabo Food & Agri Innovation Fund (Netherlands), and joined by impact fund Pymwymic (Netherlands) and existing shareholders including Yield Lab Ireland. The proceeds will enable RootWave to expand commercialisation of its RootWave Pro, a professional hand-weeder for spot weeding and treating invasive species, integrate its technology into automated agricultural weeders, and conduct further research into novel electricity-based weed killing applications.

How business models shaped our current drug development trends

V-Bio Ventures invests in Augustine Therapeutics, a VIB and KU Leuven spin-off to fight neuromuscular diseases

Magic mushrooms in modern medicine

Mining the microbiome for sustainable agriculture solutions

Closing the gender gap in biotech funding: a follow-up study

The million-dollar question: How much do you charge for a lifesaving drug?

The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags of more than a million dollars per treatment. Is the pharma industry recklessly overstepping a line here, or do they fall within current standards of value-based drug pricing? With more of these drugs soon to be rolling out of pharma pipelines, the stakes are rising high for patients, industry, governments, health insurance companies, as well as investors. It all warrants a deeper dive into the case.